Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Trial Profile

Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Crenolanib (Primary) ; Cytarabine; Etoposide; Fludarabine; Idarubicin; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors AROG Pharmaceuticals
  • Most Recent Events

    • 23 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 23 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 06 Dec 2016 Interim results (n=13) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top